Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol.
作者信息
Mukhopadhyay S, Singh M, Ogston S, Ryan G, Smyth R
机构信息
University of Dundee Department of Child Health, Ninewells Hospital and Medical School, Scotland, UK.
出版信息
J R Soc Med. 1998;91 Suppl 34(Suppl 34):25-9. doi: 10.1177/014107689809134S05.
Abstract
摘要
相似文献
1
Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol.
J R Soc Med. 1998;91 Suppl 34(Suppl 34):25-9. doi: 10.1177/014107689809134S05.
2
Evidence for using nebulised antibiotics in cystic fibrosis.
Arch Dis Child. 1999 Apr;80(4):307-9. doi: 10.1136/adc.80.4.307.
3
Pseudomonas eradication in cystic fibrosis: who will join the ELITE?
Thorax. 2010 Apr;65(4):281-2. doi: 10.1136/thx.2009.130708.
4
Mechanism of action of antibiotics in chronic pulmonary pseudomonas infection.
Adv Pharmacol. 1994;30:53-84. doi: 10.1016/s1054-3589(08)60172-6.
5
Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987.
Chest. 1988 Aug;94(2 Suppl):129S-140S. doi: 10.1378/chest.94.2.129s.
6
Cystic fibrosis and the pseudomonads.
Br J Biomed Sci. 1996 Jun;53(2):140-5.
7
Pseudomonas infection in CF (cystic fibrosis).
Thorax. 2000 Dec;55(12):1070-1. doi: 10.1136/thorax.55.12.1070b.
8
Should pulmonary exacerbations in cystic fibrosis be treated with antibiotics?
Drug Intell Clin Pharm. 1984 Oct;18(10):825-6. doi: 10.1177/106002808401801018.
9
[Making antibiotic therapy easier to use. A welcome advance for those with cystic fibrosis].
Perspect Infirm. 2011 Jul-Aug;8(4):54-5.
本文引用的文献
1
The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence.
Health Libr Rev. 1994 Dec;11(4):235-42. doi: 10.1046/j.1365-2532.1994.1140235.x.
2
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.
Thorax. 1996 Apr;51(4):364-8. doi: 10.1136/thx.51.4.364.
3
The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis.
Respir Med. 1994 Mar;88(3):203-11. doi: 10.1016/s0954-6111(05)80348-8.
4
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
JAMA. 1995 Feb 1;273(5):408-12. doi: 10.1001/jama.273.5.408.
5
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
N Engl J Med. 1994 Sep 8;331(10):637-42. doi: 10.1056/NEJM199409083311003.
6
Pseudomonas infection, allergy, and cystic fibrosis.
Arch Dis Child. 1982 Aug;57(8):582-6. doi: 10.1136/adc.57.8.582.
7
Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lancet. 1981 Nov 21;2(8256):1137-9. doi: 10.1016/s0140-6736(81)90588-2.
8
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
Am Rev Respir Dis. 1985 Oct;132(4):761-5. doi: 10.1164/arrd.1985.132.4.761.
9
Quantitative deposition of aerosolized gentamicin in cystic fibrosis.
Am Rev Respir Dis. 1987 Dec;136(6):1445-9. doi: 10.1164/ajrccm/136.6.1445.
10
Cystic fibrosis in adolescents and adults.
Ir Med J. 1991;84(4):121-4.
Zotero 插件